Navigation Links
Cogentus Pharmaceuticals Begins Clinical Study to Confirm the Full Antiplatelet Benefit of New Combination Medicine CGT-2168
Date:1/16/2008

MENLO PARK, Calif., Jan. 16 /PRNewswire/ -- Cogentus Pharmaceuticals, Inc. today announced that dosing has begun in a clinical study to confirm the full antiplatelet activity of its novel combination medicine CGT-2168. CGT-2168 is a once-daily capsule that combines clopidogrel (currently marketed by Bristol-Myers Squibb Co. and Sanofi-Aventis as Plavix(R)) with a gastroprotectant (omeprazole) to improve the gastrointestinal safety of antiplatelet therapy.

(Logo: http://www.newscom.com/cgi-bin/prnh/20071112/COGENTUSLOGO)

The crossover study (CG106) will characterize the pharmacodynamic effects of CGT-2168 compared with Plavix and will expand earlier findings of comparability. "In a previous clinical trial we demonstrated that the absorption of CGT-2168 is equivalent to that of Plavix, and that the omeprazole component within CGT-2168 does not interfere with the metabolism of the clopidogrel component," said Cogentus Chairman and Chief Executive Officer Mark A. Goldsmith, M.D., Ph.D.

An independent study published this week in the Journal of the American College of Cardiology showed that commercially available omeprazole significantly decreases the antiplatelet activity of Plavix when the two medicines are co-administered. "This finding is consistent with our own earlier clinical data that revealed an adverse drug interaction between Plavix and Prilosec(R) (marketed omeprazole), and may raise serious concerns for patients and practitioners," Dr. Goldsmith said. "However, these findings contrast with the properties we have observed with our unique formulation, CGT-2168. We expect the CG106 trial to confirm that CGT-2168 exhibits full antiplatelet activity and avoids the drug-drug interaction reported with the individual drugs on the market today."

Separately, Cogentus has begun COGENT-1, a global Phase 3 trial that will evaluate the clinical benefits
'/>"/>

SOURCE Cogentus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Cogentus to Launch Phase III Program of Novel Combination Product Designed to Reduce Bleeding Side Effect of Antiplatelet Therapy
2. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... 04, 2015 Research ... addition of the "MRI Systems Market to ... Efficiency, with Growth Driven by Developing Economies" ... Market to 2020 - Focus on Patient Comfort ... Economies" discusses the market, competitive landscape, and trends ...
(Date:8/4/2015)... and LOS ANGELES , Aug. ... DGX ), the world,s leading provider of diagnostic ... the previously announced acquisition of MemorialCare Health System,s ... a result of the transaction, patients and physicians ... innovative services and network of nearly 200 patient ...
(Date:8/4/2015)... Pharma, Inc. (Nasdaq: MEIP ), an oncology company focused ... today that Daniel P. Gold , Ph.D., President and ... Healthcare Conference on Tuesday, August 11, 2015 at 3:40 p.m. ... New York . A live webcast of the ... will be available approximately one hour after the presentation. ...
Breaking Medicine Technology:Global MRI Systems Market Outlook to 2020 - Focus on Patient Comfort and Operational Efficiency, with Growth Driven by Developing Economies 2Quest Diagnostics Completes Acquisition of MemorialCare Health System's Laboratory Outreach Service Business in Southern California 2MEI Pharma to Present at Wedbush PacGrow Healthcare Conference 2
... Sosei Group Corporation,("Sosei"; TSE Mothers Index: 4565), ... Japanese Phase III clinical trial for the,emergency contraceptive ... rights to the product in Japan from HRA ... evaluate the safety and prevented,pregnancy rate of SOH-075 ...
... Americans, WASHINGTON, July 9 In a congressional,hearing ... the,safety and importance of the research programs operated by ... absolute commitment to its patients,while expressing regret that even ... "VA has an outstanding research program, and has been ...
Cached Medicine Technology:Sosei Announces Completion of Phase III Trial for NorLevo(R) 2Secretary Reinforces VA's Commitment to Research Safety and Veteran Focus 2Secretary Reinforces VA's Commitment to Research Safety and Veteran Focus 3
(Date:8/4/2015)... ... August 04, 2015 , ... How cool is it to check in at ... The new "Now" feature will soon allow you to do just that. , Ahhaa ... other using the now feature. , Users will soon get to share what inspires ...
(Date:8/4/2015)... ... 2015 , ... World Patent Marketing, a vertically integrated manufacturer ... invention that eliminates the need to have a partner or trainer when using ... worth $30 billion," says Scott Cooper, CEO and Creative Director of World Patent ...
(Date:8/4/2015)... WASHINGTON, D.C. (PRWEB) , ... August 04, 2015 ... ... issues fellowship focused on sexual and reproductive health and rights in Indonesia for ... Journalists will visit a number of sites in Indonesia and attend the International ...
(Date:8/4/2015)... CA (PRWEB) , ... August 04, 2015 , ... An ... that found financial incentives to be a viable method for encouraging people to lose ... money on the future of their weight loss success, adding a financial incentive to ...
(Date:8/4/2015)... CA (PRWEB) , ... August 04, 2015 , ... ... are suffering from underarm sweat. Evolutions Medical & Day Spa in Santa Barbara, ... the only non-invasive, FDA cleared treatment that permanently eliminates sweat and odor glands ...
Breaking Medicine News(10 mins):Health News:Ahhaa App Soon to Release the "Now" Feature 2Health News:As The Navy Changes Body-Fat Rules, the World Patent Marketing Review Team Announces the Development of the Assisted Dumbbell Bench Rack 2Health News:As The Navy Changes Body-Fat Rules, the World Patent Marketing Review Team Announces the Development of the Assisted Dumbbell Bench Rack 3Health News:As The Navy Changes Body-Fat Rules, the World Patent Marketing Review Team Announces the Development of the Assisted Dumbbell Bench Rack 4Health News:As The Navy Changes Body-Fat Rules, the World Patent Marketing Review Team Announces the Development of the Assisted Dumbbell Bench Rack 5Health News:As The Navy Changes Body-Fat Rules, the World Patent Marketing Review Team Announces the Development of the Assisted Dumbbell Bench Rack 6Health News:UN Foundation Announces Press Fellowship to Indonesia with Focus on Women’s Health and Rights 2Health News:Article on Incentivizing Weight Loss Mirrors Similar Motivations Surrounding Weight Loss Surgery, Says Dr. Feiz & Associates 2Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 2Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 3
... , , VOORHEES, N.J., Sept. ... involving the skin, visceral organs, and airway, causing discomfort and even ... of therapies available for the prevention and treatment of angioedema, and ... acute attacks on this patient population. , , ...
... Calls on Congress to Enact Reform , ... Liability and Access today commended President Obama for acknowledging the need ... Congress to follow the President,s leadership by including reform in pending ... an address to Congress, President Obama said, "I,ve talked to enough ...
... , , , ... announced today that it has established the Edward Neurosciences Institute ... the highest level of stroke care in the world to ... (Photo: http://www.newscom.com/cgi-bin/prnh/20090910/CG73991 ) , , ...
... , , GREEN ... to keep a strong, healthy immune system. That means getting enough ... there are body stressors you can,t avoid. Environmental toxins are all ... The effects of these toxins can result in a toxic burden ...
... , , NEW BRUNSWICK, ... New York Giants vs. Washington Redskins game this Sunday, September ... new fight: supporting PSE&G Children,s Specialized Hospital, an inpatient rehabilitation ... life-changing conditions. , , Through an ...
... , ... of Cosmetic Injectables Can be a Felony , ... New York, NY (Vocus) September 10, 2009 -- One year in prison ... cosmetic injectables. As recently as August 2009, five physicians, one nurse and a practice ...
Cached Medicine News:Health News:New Directions in Angioedema: A Focus on Supportive Care and Treatment Options 2Health News:Broad Health Coalition Applauds President Obama's Commitment to Medical Liability Reform 2Health News:Edward Announces New Neurosciences Institute in Partnership With Northwestern Medical Faculty Foundation 2Health News:Edward Announces New Neurosciences Institute in Partnership With Northwestern Medical Faculty Foundation 3Health News:The #1 Stay Healthy Secret - Whole Body Cleanse(TM) from Enzymatic Therapy 2Health News:PSE&G Children's Specialized Hospital and New York Giants Team Up to Offer Text to Donate Campaign 2Health News:Physicians Coalition for Injectable Safety Urges Reporting of Suspected Illegal Solicitation or Use of Botox, Restylane, Radiesse and Others 2Health News:Physicians Coalition for Injectable Safety Urges Reporting of Suspected Illegal Solicitation or Use of Botox, Restylane, Radiesse and Others 3
... Utilizing the most complex grinding ... accurate trial lens, are specifically ... quality and precision as the ... marco RT-300 refractor. Marco custom ...
Non-Illuminated Trial Lens Set with lenses mounted in plastic frames....
Illuminated Trial Lens Set is an attractive set of trial lenses worked to a high standard of accuracy....
Minus cylinders only trial lens set....
Medicine Products: